Sign in
4

Changes in Ownership

BIOCRYST PHARMACEUTICALS INC Filed Acc 0001127602-22-025761

Chief Discovery Officer sold 31,515 shares at $13.88 ($437,428)

  • Chief Discovery Officer acquired 100,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Babu Yarlagadda S · Chief Discovery Officer

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2022-11-14 Exercise or conversion : show line 1 in the form +50,000 $1.42 $71,000 280,056 D
2022-11-14 Exercise or conversion : show line 2 in the form +50,000 $1.42 $71,000 330,056 D
2022-11-14 Sale : show line 3 in the form −31,515 $13.88 $437,428 298,541 D
Open-market sales · 31,515 sh · avg $13.88 · $437,428

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2022-11-14 Exercise or conversion : show line 4 in the form Emp. Stock Option (Right to Buy) −50,000 0 D
2022-11-14 Exercise or conversion : show line 5 in the form Emp. Stock Option (Right to Buy) −50,000 0 D
Loading xslF345X03/form4.xml…